Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens

Mohammed Saad,Richard Cantley,Wei Hao,Zixi Wang,Dafydd Thomas,Liron Pantanowitz,Xiaobing Jin
DOI: https://doi.org/10.1002/dc.25313
2024-04-03
Diagnostic Cytopathology
Abstract:Background Preferentially expressed antigen in melanoma (PRAME) has been introduced as a new melanoma marker and potential target for immunotherapy. While PRAME immunohistochemistry (IHC) is well documented in surgical pathology, similar data in cytology are limited. Metastatic melanoma is frequently diagnosed via cytology samples in which IHC plays an important role. We aimed to accordingly evaluate the performance of PRAME IHC in diagnosing metastatic melanoma in cytology samples relative to other commonly used melanoma markers. Materials and Methods The study included 156 archival cytology cases, of which 93 were melanoma cases and 63 nonmelanoma cases (controls). All cases underwent PRAME IHC staining on cell blocks. Nuclear staining of PRAME was evaluated using a quantitative and qualitative scale. Other melanocytic IHC stain results (SOX10, S‐100, Melan‐A, and HMB45) were also documented. Results PRAME was detected in tumor cells in 86% of melanoma cases, which was significantly lower than SOX10 (100%) (p
pathology,medical laboratory technology
What problem does this paper attempt to address?